

## Myoscience Announces Commercial Release of Nerve Stim Enabled iovera<sup>o</sup> Smart Tip

*New Smart Tip will be on display at 2018 Annual Assembly of AAPM&R Society in Orlando*

**FREMONT, CA (October 22, 2018)** – Myoscience, Inc. announced today the commercial release of their Nerve Stim Enabled Smart Tip 1x90mm, the latest innovative addition to Myoscience's iovera<sup>o</sup> system .

Myoscience's flagship iovera<sup>o</sup> system is a novel, non-opioid platform technology that alleviates pain by applying intense cold to targeted nerves in a process called cryoneurolysis. The pain relief is immediate and lasts up to 90 days<sup>1</sup>.

The iovera<sup>o</sup> system includes Smart Tips of different configurations to target both superficial and deep nerves. The new Nerve Stim Enabled Smart Tip can be used with most commercially available nerve stimulators to help enhance accuracy in nerve targeting. This tip received 510(k) clearance from the FDA in early 2018.

"I like the capabilities of the new iovera<sup>o</sup> Smart Tip 1x90 mm", stated Dr. Joshua A. Urban, MD, orthopedic surgeon practicing in Omaha, Nebraska. "I expect it to significantly reduce the treatment time for each patient. It will be my Smart Tip of choice for treating knee pain in my patients", he added.

"The iovera<sup>o</sup> system provides a novel approach to pain management by using cryoneurolysis to deliver immediate and long-lasting pain relief," stated Victoria Anne Brander, MD, Associate Professor, Physical Medicine & Rehabilitation at Northwestern University's Feinberg School of Medicine. "The new 90mm nerve stim enabled Smart Tip further expands the treatment potential of this system and we are excited to explore these applications."

The company will debut their new Nerve Stim Enabled Smart Tip (1x90mm) at the 2018 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly in Orlando, Florida on October 25-27, 2018. Attendees can learn more about cryoneurolysis during an educational presentation at 2PM on Friday, October 26, during this meeting. This educational session is not sponsored by Myoscience.

For additional information, please visit [www.iovera.com](http://www.iovera.com) or email us directly at [mediarelations@myoscience.com](mailto:mediarelations@myoscience.com).

### ABOUT MYOSCIENCE

---

<sup>1</sup> Radnovich, R. et al. "Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial." *Osteoarthritis and Cartilage* (2017) p1-10.

*Silicon Valley, California-based Myoscience is a privately-held medical device company committed to making its platform technology, the iovera<sup>o</sup> system, the standard of care for the treatment of peripheral nerves. The iovera<sup>o</sup> treatment is powered by a patented device that enables cryoneurolysis. The iovera<sup>o</sup> system is 510k cleared in the U.S. for the blocking of pain, the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days and general surgical use. For more information, please visit [www.iovera.com](http://www.iovera.com).*

© 2018 Myoscience. All rights reserved. iovera<sup>o</sup> is a trademark of Myoscience. MKT-0523 REV A

###